Loading
A phase 2 trial of Isatuximab, Carfilzomib, Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT05704049 by Sanofi, with 118 participants enrolled, started 2023-04-05 and due to reach its primary completion in 2025-12-22. Interventions recorded: Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast. Conditions listed: Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Isatuximab, Antiemetics for chemotherapy-induced nausea and vomiting, Sanofi, Dexamethasone.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Isatuximab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.